Is OCUL or OKYO more undervalued in 2026?

CirclFi compares Ocular Therapeutix, Inc. (OCUL) and OKYO Pharma Limited (OKYO) using 13 institutional-grade valuation models. OCUL has a Quality of Company score of 7.2/10 while OKYO scores 1.7/10.

Which is a better buy — OCUL or OKYO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OCUL and OKYO valuations compare?

OCUL at $9.15 and OKYO at $1.71 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OCUL vs OKYO Valuation Comparison 2026 — Intrinsic Value Analysis

OCUL

Biotechnology

Ocular Therapeutix, Inc.

Quality

7.2

out of 10

Value Trap

SAFE

Price

$9.15

Last close

Models

11/13

Active

OKYO

Biotechnology

OKYO Pharma Limited

Quality

1.7

out of 10

Value Trap

—

Price

$1.71

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	OCUL Fair Value	OCUL Upside	OKYO Fair Value	OKYO Upside
Bayesian DCF	Intrinsic	$4.28	-53.2%	$0.45	-73.5%
Earnings Power Value	Intrinsic	$2.78	-70.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$9.05	-1.1%	$1.04	-38.7%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OCUL vs OKYO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OCUL vs OKYO — Which Stock Is More Undervalued?

OCUL scores higher with a 7.2/10 quality rating vs OKYO's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Ocular Therapeutix, Inc. (OCUL) and OKYO Pharma Limited (OKYO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OCUL currently trades at $9.15 with a QOC of 7.2/10, while OKYO trades at $1.71 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).